Journal of Current Medical Research and Opinion
Received 15-10-2023| Revised 18-10-2023| Accepted 02-10-2023| Published Online 05-11-2023

DOI: https://doi.org/10.52845/CMRO/2023/6-11-1 ISSN (O) 2589-8779 | (P) 2589-8760

CMRO 06 (11), 1801-1812 (2023)

Original Research

Pathogenicity, Antibiotic Resistance, and Metabolites in Enterococci

Haider Hassan Ankoud[1] | Zahraa Mahdi Hadi [2] | Heba Saad Qasim Abd[3]

[1]Department of Pathological Analysis, College of Science, Thi-Qar University, Iraq.
[2]Department of Chemistry, College of Science for Women, University of Babylon, Iraq
[3]Department of Biology, Al-Rashid University College, Iraq

Abstract:

Enterococci have been connected to major infections, decreased output in the grow-out ponds and hatchery, and lowered growth rates and feed conversion in individuals that have survived the outbreak. All of these factors have had a negative impact on the overall financial productivity of the organization. The most typical steps in the pathogenesis of infectious enterococci are establishment, adhering to the cell structure of the host, tissue invasion, and an unspecific resistance defensive mechanism. Infections brought on by enterococci that displayed virulence phenotypically were shown to be more severe than those brought on by enterococci that did not express virulence in any way, according to the research that was written up and published. Because of the elevated mechanism of enterococci as causative agents that cause infections in patients whose immunity is compromised, additional research has been energized to characterize the elements and/or factors that allow bacteria to inhabit the host effectively through the barriers of the immune system, causing pathological alterations. This is being done because of the elevated mechanism of enterococci as causative agents that cause infections in patients with a compromised immune system. This is as a result of the enhanced mechanism of enterococci as a causal agent that causes infections in people whose immune systems have been impaired.

Keywords: Enterococci, Antibiotic Resistance, Metabolites, Pathogenicity.

Introduction:

Enterococci are hardy, gram-positive cocci that are common occupants of the gastrointestinal tracts of virtually all terrestrial animals, including humans. These cocci are resistant to a wide range of environmental conditions. Although they are an essential component of the microbiome, they are also capable of causing a wide range of serious diseases. These infections are most frequently observed in antibiotic-treated hospitalized patients who have an altered intestinal microbiota. In this article, we will provide an overview of the pathogenicity of enterococci, as well as a discussion of the most notable characteristics of this hospital-associated infection.

The term "enterococcus" was first used by Thiercelin at the tail end of the 19th century to refer to a saprophytic gram-positive coccus of intestinal origin that was capable of causing infection (1, 2).

This is where the term's origin can be traced. In the same year, MacCallum and Hastings (3) provided a very thorough picture of enterococcal pathogenesis. They had isolated and described an organism (now thought to be a cytolytic strain of *Enterococcus faecalis*) from a fatal case of acute endocarditis. This strain of *Enterococcus* faecalis is believed to be responsible for the disease. Bacteria that were recovered from the blood and cardiac tissue of the patient and inoculated into pure culture were able to recapitulate elements of endocarditis in animals. This satisfied Koch's Postulates and established Enterococcus as a legitimate pathogen of humans and animals. The bacteria that were recovered were given the name Micrococcus zymogenes by the researchers. These early descriptions laid the groundwork for the paradigm of enterococci as a commensal opportunist, which has since been established. After more than a century, enterococci are now widely acknowledged as the most common cause of infection in hospitals (4, 5).

Microbes belonging to the genus *Enterococcus*, most notably *E. faecalis* and *Enterococcus faecium*, are responsible for a variety of diseases that are most common in hospitalized patients. These infections include urinary tract infections, bacteremia, intra-abdominal infections, and endocarditis (6). In the United States between 2011 and 2014, enterococci were the cause of 14% of hospital-acquired infections (HAI), which is an increase from the 11% that they were responsible for in 2007 (4, 7). Enterococci are currently the third most prevalent nosocomial pathogen. Enterococci are the pathogens responsible for 5–20% of community-acquired endocarditis (8), in addition to being the cause of nosocomial infections.

Biology as well as Identifying Features

Enterococci are able to be quickly and easily isolated from a diverse array of hosts, including invertebrates, insects, and mammals. The capacity of enterococci to tolerate a variety of intrinsic host defenses in the gut is highlighted by the wide host range that they can infect (11). Enterococci are one of the first types of bacteria to colonize the gut of a human child, and as a result, they are essential components of the intestinal microbiome (12, 13). They are also widespread in the commensal microbiota of domesticated and wild animals, and they are capable of causing infections in both types of animals (14–16). As a result of the high frequency with which they are found in animal and human populations, it is simple to remove them from the surroundings that are inhabited by those hosts. They are frequently found associated with plants, in soil, and in water (17, 18). The multiple auxotrophies that enterococci possess allow them to survive in the environment, but it is unlikely that they will multiply to significant numbers there.

Enterococci were initially categorized as group D streptococci (19), but they were elevated to the level of genus in 1984 (20). This was done on the basis of nucleic acid hybridization investigations that demonstrated a more remote link to the streptococci than was previously thought. There are over 50 different species that belong to the genus Enterococcus, which appears to have diverged from its most recent common ancestor about 425 million years ago (21). Members of this genus are endowed with inherent traits that confer the ability to withstand host defenses and compete inside the digestive system. Members of this genus are also endowed with the ability to endure and spread in natural environments or hospitals, leading to the colonization of new hosts. The ability to grow over large temperature and pH ranges, the ability to resist desiccation, and the ability to grow in the presence of 6.5% sodium chloride and 40% bile salts are some of these characteristics (17).

Antibiotic Resistant Microorganisms

The difficulty of treating diseases that are brought on by enterococci is increased by the fact that these bacteria have a low susceptibility to antibiotics. This resistance can be either innate or learned over time. Cephalosporins, aminoglycosides, lincosamides, and streptogramins are unable to kill enterococci because of the bacteria's innate resistance (6, 22). The fact that enterococci have their own intrinsic resistance makes it highly likely that they will be able to acquire additional resistances on mobile genetic elements. In the patient who has been treated with antibiotics, enterococci accumulate to high numbers (23), and

they co-exist in intimate association with other overtly antibiotic-resistant microbes. This is the precise environment to enhance the probability of contact between enterococci and other species harboring new resistances on mobile elements, leading to element acquisition.

Because many -lactams are ineffective against enterococci, researchers have been looking for alternative therapeutic methods. As a result of the discovery that aminoglycosides were synergistic with beta-lactams and could attain cidality (24), combination therapy became the standard of care for the treatment of bacterial infections.

In contrast, aminoglycoside resistance in enterococci was described only a few years later (25) and was determined to be the result of the acquisition of a plasmid-borne resistance component. This was discovered to be the case. Aminoglycoside-modifying enzymes, particularly a bifunctional enzyme (26), are what confer high-level resistance to aminoglycosides, and mobile elements that bestow this feature have diffused throughout the enterococci (27). Enterococci that expressed a beta-lactamase have been found (28), further undermining the efficacy of combination therapy; however, these enterococci remain surprisingly uncommon.

Vancomycin first appeared on the market in the late 1950s (29), but its use was restricted to hospitalized patients with beta-lactam allergies and infections caused by organisms resistant to other antibiotics (30). This was mostly due to vancomycin's limited spectrum of activity and its requirement for intravenous dosage. After it was discovered that vancomycin was effective against aminoglycoside-resistant enterococci (31), it rapidly rose to prominence as a prominent alternative treatment throughout the late 1970s and early 1980s (32). However, resistance to vancomycin did not appear until the middle of the 1980s; it first appeared in Europe (33, 34), and then it appeared in the United States (35). There is currently widespread dissemination of vancomycin-resistant enterococci over the world, with as much as 80% of E. coli being resistant. isolates of faecium in some institutions having resistance to the antibiotic vancomycin (4, 36).

Vancomycin resistance in enterococci was rapidly increasing at the beginning of the 21st century, which caused worry because it marked the loss of an important bactericidal medication that was used as a last resort.

Although daptomycin was proven to be effective against vancomycin-resistant enterococci (VRE) (37), the pace of daptomycin-resistance development during the course of treatment was found to restrict its utility (38–40). In resistant isolates, changes were found in multiple genes that influence the content and charge of cell membranes. These genes include glycerophosphoryldiester-phosphodiesterase gdpD, cardiolipin synthase cls, and the stress-sensing response component liaF (41, 42). *Staphylococcus aureus* was shown to modify several different pathways in order to become resistant to daptomycin (43), which makes it difficult to have a thorough knowledge of the mechanism by which it works. In addition, resistance-conferring mutations that are produced from enterococci in vitro only partially overlap with those that emerge in vivo. This could be because of changes in the lipid incorporation from the environment into the enterococal membrane (44). Lipidomic studies of daptomycin-resistant strains exhibited different lipid profiles compared to sensitive strains. These variations were notably noticeable in phosphatidylglycerols, cardiolipins, and glycolipids (45).

The first oxazolidinone antibiotic, linezolid, was approved by the FDA in the year 2000. However, shortly after its introduction into clinical usage, linezolid-resistant VRE strains began to appear in the United States in the year 2001 (46), and in the United Kingdom in the year 2002 (47). The resistant isolates were sequenced, and the results showed that the 23S ribosomal RNA subunit (48) included a G2576U mutation. This mutation was also observed in resistant organisms that were isolated from a gnotobiotic mouse model of infection (49). It was discovered that the occurrence of this mutation was dependent on the amount of antibiotic that made it to the intestine. Following further investigation, it was discovered that a linezolid-resistant strain from Thailand had

acquired the cfr methyltransferase on a plasmid. This resulted in the methylation of position A2503 in the 23S rRNA, which caused high-level resistance (50).

The glycylcycline tigecycline is an additional antibiotic that has proven to be effective in the treatment of vancomycin-resistant enterococci. It has been used successfully to treat VRE infection, both on its alone and in combination with other antibiotics; nevertheless, resistance has also developed to this drug. A study was done on 73 strains of E. coli that were resistant to tigecycline. faecium as well as *E. faecalis* isolates that were collected between 2007 and 2015 had alterations in a number of efflux pumps, which were reported to be related with tigecycline resistance (51). In a series of passages, *E. faecium* in vitro in the presence of tigecycline selected for mutations in the ribosomal protein subunit rpsJ; however, the functional validity of this mutation has not yet been established (49). Despite this, it appears that enterococci are able to develop resistance to antibiotics of every class that have been utilized in clinical settings up until this point.

The endurance of the environment:

Epidemiological studies highlight person-to-person transmission of endemic strains within the hospital (51), which suggests that enterococci remain for extended periods of time in the hospital setting. This is implied by the clonality of the infection, which also suggests that enterococci persist. Transmission is place when an infected individual comes into contact with a healthcare provider or an inanimate object such as a bedrail, nursing station keypad, hospital draperies, or ear-probe thermometer (50). Enterococci have a particularly high resistance to the antiseptics and disinfectants that are typically used, as well as to ultraviolet radiation, hunger, and desiccation (52). The capability of enterococci to persist in nutrient-deficient environments as well as desiccation has prompted some researchers to hypothesize that as an adaptation to low growth conditions, enterococci may enter a viable but non-culturable state, although the specifics of such a process have not yet been explored.

Numerous studies have focused on E. coli in their investigation of environmental resiliency. faecalis (51), which can develop a tolerance to levels of bile salts and detergents, such as sodium dodecyl sulfate (SDS), that would otherwise be lethal, provided that the bacteria were first subcultured in the presence of levels that were below the lethal threshold. This phenomenon almost certainly plays a role in the capacity of enterococci to withstand the cleaning procedures utilized by the majority of hospitals as part of their infection control programs. The adaptive response to environmental disturbances is governed by regulatory systems. In the research carried out by Hancock and Perego, the inactivation of a response regulator that was given the designation RR06 resulted in an increased susceptibility to the effects of heat stress (growth at 46°C) and detergent stress (0.003% SDS). Le Breton and colleagues shown that another response regulator called RR10 inhibits the heat shock proteins DnaK and GroEL from functioning properly. The inactivation of the rr10 gene led to increased acid sensitivity, but it also improved survival at temperatures of 50 degrees Celsius.

A wide variety of enterococcal species, including clinical isolates as well as species that have never been reported to be linked with human infection, were examined for resistances to chemical compounds as well as environmental stresses. The purpose of this comparison was to determine the genetic components to this intrinsic ruggedness. It was shown that all enterococci are inherently far more resistant to the majority of assaults than other microorganisms that are related to them. This finding suggests that many of the fundamental characteristics were acquired by the genus as it branched out from its ancestors. The two species of enterococci that are most dangerous to humans are *E. coli* and VRE. faecalis as well as *E. faecium*, which demonstrated the highest level of tolerance to both hunger and drying out (21). Additionally, considerable levels of resistance have been seen in both of these species to the widely used hospital disinfectants chloroxylenol and chlorhexidine. Researchers were able to narrow down the molecular pathways that contribute to these traits to a collection of 126 genes that differentiated

enterococci from their forebears. In addition, the two-component system ChtRS was found to be a significant regulator of chlorhexidine resistance in E. coli very recently. faecium. faecium.

Mechanisms Contributing to Disease:

It is necessary for enterococci to initially overcome a number of obstacles before they may cause disease. The capacity to overcome the resistance to colonization that is offered by competing microorganisms as well as host defenses such as gastric acid and bile is an initial barrier that must be overcome in order to colonize the intestinal tract. The bacteria in this reservoir have the potential to multiply and then spread to other locations that are susceptible to infection. A fundamental assumption that can be derived from such a model is that the chance of infection should be a function of the intestinal load of bacteria that are present in the gut reservoir. In other words, the bigger the quantity of bacteria in the gut, the higher the probability that a possible infection site will be contaminated with bacteria in sufficient numbers to defeat the host's defenses. Indeed, it has been demonstrated that colonization of the gastrointestinal system is directly connected with an increased risk of infection. Infection occurs when enterococci overpower the host's defenses, multiply at rates that exceed clearance, and when pathologic alterations ensue either directly as a result of the activity of the toxin or indirectly as a result of bystander damage caused by the inflammatory response. Infection can also develop when enterococci replicate at rates that exceed clearance.

The colonization of humans:

Enterococci are fundamental to the human microbiome yet account for a relatively small percentage of its total members. The presence of two different species, E. faecalis as well as *E. faecium*, which shows that neither evolved in humans but rather probably entered the primate lineage early and from species taken from below on the food chain. This is because of the same abundance of both of these organisms. Each of E. faecalis as well as E. faecium are detected in human feces in quite high numbers (105-107 organisms per gram), but they normally account for less than 1% of the total microbial community. The difficulty that an organism has in colonizing a population that is already stable and established is referred to as its "colonization resistance". The inborn defense system of the gastrointestinal tract relies heavily on this mechanism.

In most cases, antibiotic-induced disturbance of the community structure is related with the colonization and growth of hospital-adapted lineages of enterococci. Because of this, proper management of the human microbiome in both healthy and diseased states is a potentially fruitful technique for reducing the risk of infections occurring in hospitals.

The acidic environment of the stomach is hostile to the majority of germs, including enterococci, and thus serves as a significant obstacle to the invasion of the gut consortium and colonization of orally acquired pathogens. When this barrier is breached, there is an increased risk of oral acquisition of enterococci from an environment that is polluted. Patients who are being treated for stress ulcers in particular are given H2-receptor antagonists as a preventative measure in intensive care units. As a result of this action, the pH of the patient's body rises from pH 2 to pH 3.5–5.3, depending on the antagonist that is being used. H2-receptor antagonists were demonstrated to stimulate colonization of the small bowel as well as the translocation of enteric bacteria from the intestinal tract to extraintestinal tissues in a study that was conducted by Basaran et al. The study was conducted in rats.

The capacity of enterococci to survive in an acidic pH environment has been investigated by a number of research. It was proven by Flahaut et al. that exposure of *E. faecalis* to a pH level that was below the lethal threshold (pH 4.8) for 15–30 minutes protected the organism against a challenge that would normally be lethal at pH 3.2.

This finding suggests an adaptive response to altering acid stress. It was demonstrated by Suzuki and colleagues that an *E. faecalis* mutant lacking F1-F0 H+-ATPase function was unable to grow when the pH was lowered to less than 6. The H+-

ATPase in E is responsible for regulating the pH of the cytoplasm. faecalis through the process of proton extrusion, and it has been demonstrated that this enzyme is activated at low pH. Teng et al discovered a two-component regulatory system that they dubbed EtaRS. This system appears to be involved in both the response to acid stress and the pathogenicity of the organism. In a model of murine peritonitis, the inactivation of the response regulator known as EtaR leads in increased acid sensitivity and lower pathogenicity.

The stability of an adult, diverse population of bacteria in the gut is another factor that contributes to colonization resistance. The use of broad-spectrum antibiotics, many of which have very low or no anti-enterococcal effect, destabilizes this community by removing sensitive members, which opens the door for new species to move in and establish themselves. In a study that was aimed to investigate the continued presence of vancomycin-resistant E. coli and the density of their colonization, researchers found that *E. faecium* in a mouse model, Donskey et al. shown that the reduction of the anaerobic microflora through the use of antimicrobials that target this microbial population resulted in higher colonization density as well as prolonged VRE persistence. This finding shows the significance of the anaerobic flora in inhibiting the proliferation of enterococci inside the intestinal milieu. There have been a number of other studies that have investigated the factors that contribute to the overgrowth of enterococci, particularly VRE, in the GI tracts of hospitalized patients. Clearance of commensals and an increase in the number of enterococci can result from treatment with broad-spectrum antibiotics, particularly cephalosporins and metronidazole, to which enterococci have an innate resistance. Patients who are hospitalized and treated with these medications may, in the most severe cases, acquire a near monoculture of VRE in their intestines, putting them at an increased risk for enterococcal bacteremia and other enterococcal infections. A number of factors, including but not limited to E. faecium in an antibiotic-troubled gut include lower expression of the host innate immunity component RegIII. This is because the loss of gram-negative members of the gut microflora (90) indirectly causes this reduction in expression. The synthesis of RegIII is dependent on the signaling that occurs through TLR-5 and IL-22, and it has been demonstrated that supplementation with TLR agonists can restore RegIII expression and suppress E. coli. development of faeces. It has been demonstrated that the IL-22 signaling pathway, and in particular the IL-22 receptor, is necessary for E. coli infection in mice. resistance to faecalis colonization faecalis. Mice lacking the il22ra1 gene were shown to be especially vulnerable to E. coli infection. expansion of faecalis, which led to later systemic dispersion. This constraint placed on E. Fucosylated glycans play a role in the regulation of faecalis outgrowth; however, these glycans are reduced in Il22ra1-deficient mice. It has been demonstrated that taking oral supplements of fucosylated glycans increases the variety of the microbiota in the gut and restores the growth restriction of *E. coli*. the faecalis strain.

Hospital-adapted strains of enterococci are endowed with qualities that allow them to colonize microniches that are likely less appropriate for colonization by commensal strains. These properties allow hospital-adapted strains of enterococci to colonize microniches in addition to antibiotic and host immunological factors. For instance, there are some strains of *E. coli* that are connected with hospitals. faecalis have an extra bile salt hydrolase in their genome. *E. faecalis* is also responsible for the production of extracellular superoxide, which can cause DNA damage in colonic epithelial cells and chromosomal instability. These effects may be connected to local inflammation, changes in the nutritional characteristics of the mucosa, and the development of colorectal cancer. There is evidence to suggest that enterococci may play a role in inflammatory bowel disease (IBD), Crohn's disease (CD), and ulcerative colitis (UC). A high prevalence of enterococci, in particular E. faecium, is found in greater quantities in the feces of people with CD as opposed to healthy controls. Elevated levels of *E. faecalis* prevalence, as well as anti-E. antibodies against faecalis have also been found in people suffering with UC. Mice devoid of germs and

lacking IL-10 that were then inoculated with *E. faecalis* develop chronic symptoms that are similar to IBD, showing the capacity of the bacteria to prolong inflammation in the gut. A subgroup of the virulence factors in E. coli is known as E. faecalis, such as the metalloprotease GelE, enterococcal polysaccharide antigen Epa, and cell surface-associated lipoprotein Lgt, were demonstrated to have an influence on the production of inflammatory bowel disease in these mice.

The enterococci in the gut have to compete with other microorganisms for space, binding sites, and nutrients in order to survive. It has been known for a long time that enterococci are extremely productive manufacturers of bacteriocins, the majority of which are encoded by mobile elements. Plasmid pPD1, which is carried by some strains of *E. faecalis* strains, encoding a bacteriocin that is inhibitive to other *E. coli* strains. faecalis strains, which can ultimately, under certain circumstances, lead to the replacement of strains *in vivo*. Most significantly.

Infection of the Urinary Tract:

Over 20,000 instances of catheter-associated urinary tract infections (CAUTI) were reported to the CDC National Healthcare Safety Network between the years 2011 and 2014. Enterococci were the most often isolated gram-positive bacteria from these infections. The study was conducted on a population of nosocomial illnesses that occurred between 2011 and 2014. A little more than half of these infections were due to *E. coli*, which was followed by "other Enterococcus species" (less than thirty percent), and E. coli. faecium (less than twenty percent). Most worrisome was the fact that ~85% of E. isolates of faecium were resistant to vancomycin, and the proportion of resistant isolates was growing each year. faecium isolates were resistant to vancomycin.

A limited number of research have been conducted with the purpose of gaining an understanding of the interaction of enterococci with uroepithelial tissue. In their study, Kreft and colleagues demonstrated that the plasmid-encoded aggregation material may play a role in the process by which enterococci adhere to renal epithelial cells. *E. faecalis* bacteria that possessed the pheromone-responsive plasmid pAD1, or any of the other isogenic versions of this plasmid, were able to bind to the LLC-PK cultured pig renal tubular cell line with a greater degree of success than bacteria that lacked this plasmid. Their research also shown that a synthetic peptide that contained the fibronectin motif, Arg-Gly-Asp-Ser, has the ability to block the binding reaction. The interaction that takes place between fibronectin and eukaryotic surface receptors belonging to the integrin family is mediated by this structural motif. Guzman and his colleagues investigated the capability of several strains of *E. faecalis* that was isolated from either endocarditis or urinary tract infections has the ability to adhere to the epithelial cells of the urinary tract as well as the Girardi heart cell line. It appears that environmental modifications can facilitate interactions with host tissues. Isolates from urinary tract infections attached to urinary tract epithelial cells in vitro, but strains from endocarditis adhered easily to the Girardi heart cell line. It was demonstrated by Shankar et al. that the *E. faecalis* Esp surface protein co-localizes in the bladder in an ascending urinary tract infection model, but not in the kidneys; this suggests that the protein has tissue specificity for the bladder epithelium. One of these strains, AS14, was subjected to transposon mutagenesis with Tn916, and mutants with altered collagen IV and laminin binding were identified. Tomita et al. demonstrated that highly adherent enterococcal UTI strains recognize the extracellular matrix proteins fibronectin, laminin, and collagen types I, II, IV, and V. 13 of the 14 single transposon insertion mutants matched to the newly discovered Ace protein, which was discovered recently. The level of adhesion that mutants had to collagen IV and laminin was anywhere from one to two orders of magnitude lower than that of the wild-type strain; however, the collagen binding protein found in S., the collagen-binding proteins Ace (*E. faecalis*) and Acm (*E. faecium*) were initially identified. aureus on lines 138 and 139. The capacity of the majority of *E. faecalis* Ace-positive bacteria to adhere to collagen and laminin was significantly reliant on growth temperature. Binding occurred at 46°C, but not at 37°C.

Infections at the site of surgery:

Enterococci are one of the most prevalent bacteria to cause surgical site infections at all anatomical sites, including the eye. The eye provides a one-of-a-kind opportunity to visualize the progression of such an infection utilizing equipment that is easily accessible. When a small number of organisms are injected into the vitreous of a rabbit or mouse, they can be immediately investigated using an ophthalmoscope or a slit lamp. Additionally, diminishing organ function can be quantitatively quantified by electroretinography. Enterococci rapidly proliferate at this site, with a 10ul injection of enterococci suspended in PBS surviving as a light-refracting bead after the fast multiplication of enterococci at this site. A layer of fibrin is deposited on the surface of the tiny bead after a few hours have passed. After around 12 hours, the micro capillaries in the retina start to dilate, and then they turn white as adhering neutrophils coat them and cause them to become covered in neutrophils. After approximately twenty-four hours, one may observe neutrophils migrating from arteries in the head of the optic nerve to the source of the infection. These many measuring parameters make it possible to analyze several processes in the pathogenesis of an infection and to define the roles of various features presented by the bacteria. In this paradigm, the enterococcal cytolysin makes a significant contribution to organ death. Unfortunately, this damage cannot be reversed by treatment with antibacterial or anti-inflammatory agents that are otherwise successful. In contrast, identical infections that began with isogenic cytolysin knockout strains responded favorably to antibacterial and anti-inflammatory treatment, resulting in complete resolution of the infection and no impairment of organ function. Using this model, it was discovered that both the GelE and SprE proteases, both of which are controlled by the Fsr quorum-regulated system, provide measurable contributions to virulence in the rabbit model of endophthalmitis.

Metabolites:

In addition to the proteins that are secreted, *E. faecalis* as well as *E. faecium* have also been demonstrated to create hazardous oxygen metabolites, which are capable of causing damage to cells as well as organs. Moy et al. established that E. coli can be found in worms by using a worm model. The quantities of hydrogen peroxide produced by faecium are high enough to cause harm to cells. *E. faecium* transposon insertion mutants that changed C were found and identified. elegans killing activity and displayed changed levels of hydrogen peroxide generation. elegans. The mutation of a gene producing a NADH oxidase led to a decrease in the production of hydrogen peroxide and a slower rate of nematode death. On the other hand, the mutation of a gene encoding a NADH peroxidase led to an increase in the levels of hydrogen peroxide and a more rapid rate of nematode death. *E. coli* can grow in a variety of settings, depending on the culture. faecium are capable of producing various amounts of hydrogen peroxide, and this production seems to connect inversely with the survival of nematodes.

According to the findings of one study, the overwhelming majority (87 out of 91) of *E. faecalis* strains that have been tested produce superoxide (O), whereas *E. faecium* strains do not. isolates of faecium (5/13) did so significantly less frequently. The authors of the study hypothesized that the impacts of oxygen radicals, which are known to damage membranes, would also exacerbate cellular damage to adjacent intestinal epithelial cells. The formation of extracellular superoxide and hydrogen peroxide has been found to damage colonic epithelial cell DNA. This was demonstrated through the use of evidence. The explanation for why *E. faecalis* produces extracellular oxygen radicals because this oxygen radical is a result of an incomplete respiratory chain. The fact that this oxygen radical is produced by faecalis arises from the fact that this oxygen radical is a byproduct. *E. faecalis* is able to effectively respire because it is capable of reconstituting a cytochrome complex in the presence of exogenous heme. It would appear that the fact that enterococci produce a byproduct that is harmful to their host is an unintended consequence of the incomplete respiration that they engage in.

Conclusion:

Enterococci are very well adapted for survival and persistence in a wide variety of hostile habitats, including inanimate surfaces in the hospital environment and at sites of infection. This makes enterococci a potential source of infection in a variety of settings. This intrinsic ruggedness probably had a part in creating opportunities for drug-resistant enterococci to interface with other blatantly drug-resistant bacteria and gain additional resistances on mobile components. Nosocomial infections have become one of the most difficult treatment problems to solve as a direct result of the rapid growth of antibiotic resistance among hospital-adapted enterococci. After the addition of around a quarter of a genome's worth of additional DNA that was transferred by mobile elements, there are certainly many more traits that have been gained that enable enterococci endure and spread in the hospital context, and disease that has yet to be defined. These features help enterococci cause disease that has yet to be identified. There is still a great deal of mystery surrounding these old and hardy microorganisms.

References:

1. MacCallum WG and Hastings TW. 1899 A Case of Acute Endocarditis Caused by Micrococcus Zymogenes (Nov. Spec.), Together with a Description of the Microorganism. Journal of Experimental Medicine 4:521–534.
2. Yehia N, Aly A, Al-Mousa HH, Sayed E, and Al Asar M. Infections acquired at a medical-surgical intensive care unit in 2008 due to a nosocomial source. Med Principles and Practice 17:373–377.
3. C.J. Kristich, L.B. Rice, and C.A. Arias. 2014 Enterococcal Infection: Treatment Options and the Development of Antibiotic Resistance. Drug-Resistant Infections Can Be Caused by Enterococci Ranging from Commensals to Lead.
4. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, and Fridkin SK were the researchers who contributed to this study. Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007 for the National Healthcare Safety N. Source Infect Control Hosp Epidemiol Infect Control Hosp Epidemiol 29. 2008
5. Y. Ike, M. S. Gilmore, D. B. Clewell, and N. Shankar. 2014 Enterococci Enterococci: From Commensals to Leading Causes of Drug Resistant Infection. 2014 Enterococci Enterococci.
6. EGGESB M, MOEN B, PEDDADA S, BAIRD D, RUGTVEIT J, MIDTVEDT T, BUSHEL PR, SEKELJA M, RUDI K. EGGESB M, MOEN B, PEDDADA S, BAIRD D. 2011 Research on the development of the microbiota in the guts of infants who were not subjected to any medical procedures. APMIS 119, verses 17 to 35.
7. Both Lawley and Walker were TD. 2013 Resistance to intestinal colonization in 2013. 138:1–11 of the journal Immunology.
8. Both A. Jung and S. Rautenschlein. 2014 Detailed report of an infection caused by Enterococcus cecorum in a broiler flock in Northern Germany. BMC Veterinary Research 2010:311.
9. Martin J.D. and John O. Mundt. 1972 The First Report of Enterococci in Insects. Applied and Environmental Microbiology 24:575–580.
10. Mundt, Joseph O. 1963 The discovery of enterococci living on plants in their natural environment. 11:141–4 of the journal Appl. Microbiol.
11. Schleifer K.H. and R. Kilpper-Balz. The bacteria Streptococcus faecalis and Streptococcus faecium were moved into the genus Enterococcus norn in the year 1984. once known as comb. Enterococcus faecalis. in addition to Enterococcus faecium comb. nov. nov. Int. J. Syst. Bacteriol., International Union of Microbiological Societies, 34:31–34.
12. 2017 Tracing the Enterococci from Paleozoic Origins to the Hospital by Lebreton F, Manson AL, Saavedra JT,

Straub TJ, Earl AM, and Gilmore MS. 849–861.e13 on cell number 169.

13. Xavier JB, Lipuma L, Ubeda C, Goldberg J. 2012 Intestinal dominance and the risk of bacteremia in patients who were receiving allogeneic hematopoietic stem cell transplantation. The Clinical Infectious Diseases 55:905–914.

14. The authors' names are Moellering RC, Wennersten C, and Weinberg AN. Penicillin and gentamicin worked together more effectively against enterococci in 1971. Reference: Journal of Infectious Diseases 124:207–209.

15. JJ, Gilmore KS, Courvalin P. 167:631-638 in Journal of Bacteriology. [Publication Number: 3015884]

16. Murray BE. Enterococci producing beta-lactamase in the year 1992. Antibacterial and Chemotherapeutic Agents and Chemotherapy 36:2355–2359. [Publication Number: 1489177]

17. JE Geraci, FR Heilman, DR Nichols, GT Ross, and WE Wellman are the authors of this study. Some laboratory and clinical experiences with the newly discovered antibiotic vancomycin in 1956. Mayo Clinic Proceedings, Volume 31: page 564 to page 582.

18. Kaye D., Rahimtoola SH, Bisno AL, Dismukes WE, Durack DT, Kaplan EL, Karchmer AW, Sande MA, Sanford JP, Watanakunakorn C, and Wilson WR. Antimicrobial Treatment of Infectious Endocarditis Caused by Viridans Streptococci, Enterococci, and Staphylococci (published in 1989). JAMA (Journal of the American Medical Association) 261, page 1471.

19. HA Kirst, DG Thompson, and TI Nicas. 1998 was the historical year in which vancomycin was used [1]. Chemotherapy using Antimicrobial Agents.

20. Uttley AH, Collins CH, Naidoo J, and George RC. 1988 Enterococci resistant to the antibiotic vancomycin. 1:57–58 of the Lancet.

21. Kissinger J., Sahm DF, Gilmore MS, Murray PR, Mulder R., Solliday J., and Clarke B. Vancomycin-resistant Enterococcus faecalis was subjected to in vitro susceptibility tests in the year 1989. Chemotherapy and Antimicrobial Agents 33:1588–1591.

22. CA Arias and BE Murray were cited. 2008 A review of the emergence of drug-resistant enterococcal infections and their management was published in the Expert Review of Anti-Infective Therapy. Taylor & Francis, if you will.#

23. Lesho E, Wortmann GW, Craft D, and Moran KA. 2006 Letters to the Editor De Novo Daptomycin Nonsusceptibility in a Clinical Isolate. J Clin Microbiol 44.

24. Long JK, Choueiri TK, Hall GS, Avery RK, Sekeres MA. 2005 DAPTOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM Daptomycin-Resistant Enterococcus faecium in a Patient With Acute Myeloid Leukemia CASE REPORT. Mayo Clin Proc 80:1215–1216.

25. Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS. 2011 Genetic basis for daptomycin resistance in enterococci. Antimicrob Agents Chemother 55:3345–3356. [PubMed: 21502617]

26. Saito HE, Harp JR, Fozo EM. 2014 Incorporation of exogenous fatty acids protects Enterococcus faecalis from membrane-damaging agents. Appl Environ Microbiol 80:6527–6538. [PubMed: 25128342]

27. Hines KM, Waalkes A, Penewit K, Holmes EA, Salipante SJ, Werth BJ, Xu L. Characterization of the Mechanisms of Daptomycin Resistance among Gram-Positive Bacterial Pathogens by Multidimensional Lipidomics.

28. Auckland C, Teare L, Cooke F, Kaufmann ME, Warner M, Jones G, Bamford K, Ayles H, Johnson AP. 2002 Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J Antimicrob Chemother 50:743–6. [PubMed: 12407134]

29. Bourgeois-Nicolaos N, Massias L, Couson B, Butel M, Andremont A, Doucet-Populaire F. 2007 Dose Dependence of Emergence of Resistance to Linezolid in Enterococcus faecalis In Vivo. J Infect Dis 195:1480–1488. [PubMed: 17436228]

30. Cattoir V, Isnard C, Cosquer T, Odhiambo A, Bucquet F, Guérin F, Giard J-C. 2015 Genomic analysis of reduced susceptibility to tigecycline in Enterococcus faecium. Antimicrob Agents Chemother 59:239–44. [PubMed: 25348531]

31. Figdor D, Davies JK, Sundqvist G. 2003 Starvation survival, growth and recovery of Enterococcus faecalis in human serum. Oral Microbiol Immunol 18:234–239. [PubMed: 12823799]

32. Heim S, Del Mar Lleo M, Bonato B, Guzman CA, Canepari P. 2002 The Viable but Nonculturable State and Starvation Are Different Stress Responses of Enterococcus faecalis, as Determined by Proteome Analysis. J Bacteriol 184:6739–6745. [PubMed: 12426365]

33. Flahaut S, Frere J, Boutibonnes P, Auffray Y. 1996 Comparison of the bile salts and sodium dodecyl sulfate stress responses in Enterococcus faecalis. Appl Environ Microbiol 62:2416–2420. [PubMed: 8779581]

34. Flahaut S, Hartke A, Giard JC, Auffray Y. 1997 Alkaline stress response in Enterococcus faecalis: adaptation, cross-protection, and changes in protein synthesis. Appl Environ Microbiol 63:812–4. [PubMed: 9023964]

35. Giard JC, Hartke A, Flahaut S, Boutibonnes P, Auffray Y. 1997 Glucose starvation response in Enterococcus faecalis JH2–2: Survival and protein analysis. Res Microbiol 148:27–35.

36. Laplace JM, Thuault M, Hartke A, Boutibonnes P, Auffray Y. 1997 Sodium hypochlorite stress in Enterococcus faecalis: Influence of antecedent growth conditions and induced proteins. Curr Microbiol 34:284–289. [PubMed: 9099628]

37. Le Breton Y, Boël G, Benachour A, Prévost H, Auffray Y, Rincé A. 2003 Molecular characterization of Enterococcus faecalis two-component signal transduction pathways related to environmental stresses. Environ Microbiol 5:329–337. [PubMed: 12713459]

38. Garsin DA, Frank KL, Silanpää J, Ausubel FM, Hartke A, Shankar N, Murray BE. 2014 Pathogenesis and Models of Enterococcal InfectionEnterococci: From Commensals to Leading Causes of Drug Resistant Infection. Massachusetts Eye and Ear Infirmary.

39. Johnson A 1994 The pathogenicity of enterococci. FEMS Microbiol Rev 33:1083–1089.

40. Noble CJ. 1978 Carriage of group D streptococci in the human bowel. J Clin Pathol 31:1182–1186. [PubMed: 107199]

41. Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JI, eds. (2000). Gram-Positive Pathogens. ASM Press.

42. Fisher K, Phillips C (June 2009). "The ecology, epidemiology and virulence of Enterococcus". Microbiology. 155 (Pt 6): 1749–57.

43. Schleifer KH, Kilpper-Balz R (1984). "Transfer of Streptococcus faecalis and Streptococcus faecium to the genus Enterococcus nom. rev. as Enterococcus faecalis comb. nov. and Enterococcus faecium comb. nov". Int. J. Syst. Bacteriol. 34: 31–34.

44. Lebreton F, Manson AL, Saavedra JT, Straub TJ, Earl AM, Gilmore MS (2017) Tracing the Enterococci from Paleozoic origins to the hospital. Cell 169(5):849-861.e13. doi: 10.1016/j.cell.2017.04.02

45. Ryan KJ, Ray CG, eds. (2004). Sherris Medical Microbiology (4th ed.). McGraw Hill. pp. 294–5. ISBN 0-8385-8529-9.

46. Fiore, Marco; Maraolo, Alberto Enrico; Gentile, I. Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis". World Journal of Hepatology. 2017; 9 (30): 1166–1175.

47. Pelletier LL Jr. (1996). "Microbiology of the Circulatory System". In Baron S; et al. (eds.). Baron's Medical Microbiology (4th ed.). Univ of Texas Medical Branch. ISBN 0-9631172-1-1.

48. Zhanel GG, Hoban DJ, Karlowsky JA (January 2001). "Nitrofurantoin is active against vancomycin-resistant enterococci". Antimicrobial Agents and Chemotherapy. 45 (1): 324–6.

49. Guardado R, Asensi V, Torres JM, Pérez F, Blanco A, Maradona JA, Cartón JA (2006). "Post-surgical enterococcal meningitis: clinical and epidemiological study of 20 cases". Scandinavian Journal of Infectious Diseases. 38 (8): 584–8.

50. Kurup A, Chlebicki MP, Ling ML, Koh TH, Tan KY, Lee LC, Howe KB (April 2008). "Control of a hospital-wide vancomycin-resistant Enterococci outbreak". American Journal of Infection Control. 36 (3): 206–11.

51. Batts, D. H.; Lavin, B. S.; Eliopoulos, G. M. (2001). "Quinupristin/dalfopristin and linezolid: spectrum of activity and potential roles in therapy--a status report". Current Clinical Topics in Infectious Diseases. 21: 227–251. ISSN 0195-3842. PMID 11572153

52. Collins, L A; Malanoski, G J; Eliopoulos, G M; Wennersten, C B; Ferraro, M J; Moellering, R C (March 1993). "In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms". Antimicrobial Agents and Chemotherapy. 37 (3): 598–601. doi:10.1128/aac.37.3.598. ISSN 0066-4804. PMC 187713. PMID 8460927.

53. Singh, Kavindra V.; Weinstock, George M.; Murray, Barbara E. (June 2002). "An Enterococcus faecalis ABC Homologue (Lsa) Is Required for the Resistance of This Species to Clindamycin and Quinupristin-Dalfopristin". Antimicrobial Agents and Chemotherapy. 46 (6): 1845–1850.

How to cite this article: AAnkoud, H. H. ., Hadi, Z. M. ., & Qasim Abd, H. S. . (2023). Pathogenicity, Antibiotic Resistance, and Metabolites in Enterococci. Journal of Current Medical Research and Opinion, 9(11), 1801–1812. https://doi.org/10.52845/CMRO/2023/6-11-1